Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2014

Planlagt Fastgjort Låst Flyttet Genmab
627 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • investor1989I Offline
    investor1989I Offline
    investor1989
    wrote on sidst redigeret af
    #454

    Mit kursmål er 1000 i 2020 og vil ikke kalde det blueskye. Men det skal jo så tilbagediskonteres med eksempelvis 15% i 6 år hvilket vil gøre at mit kursmål pt. vil være ca. 400

    1 Reply Last reply
    0
    • nohopeN Offline
      nohopeN Offline
      nohope
      wrote on sidst redigeret af
      #455

      ok -

      1 Reply Last reply
      0
      • nohopeN Offline
        nohopeN Offline
        nohope
        wrote on sidst redigeret af
        #456

        lusede 15 % i rente - 🙂

        1 Reply Last reply
        0
        • investor1989I Offline
          investor1989I Offline
          investor1989
          wrote on sidst redigeret af
          #457

          Men ligner amerikanerne gør lidt. Over 220 nu. men håber du forstod mit indlæg nohype? at ens langsigtede kursmål 6-7 år ude i fremtiden selvfølgelig skal tilbagediskonteres hvorimod at MLI's nuværende 570 blue sky allerede er tilbagediskonteret

          1 Reply Last reply
          0
          • investor1989I Offline
            investor1989I Offline
            investor1989
            wrote on sidst redigeret af
            #458

            en WACC på 15% vil jeg bruge når jeg tilbagediskonterer biotek ifht. den store risiko det jo har. Novod og Bowers ligger også på en 11-12% i WACC så vidt jeg husker

            1 Reply Last reply
            0
            • nohopeN Offline
              nohopeN Offline
              nohope
              wrote on sidst redigeret af
              #459

              Jeg tror jeg forstod det, tak.

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #460

                btw har jeg en rigtig god ide pt. ala bakka og protector. En fantastisk billig, valueaktie. Skal fortælle dig om den om en måneds tid. Skal lige se deres halvårsregnskab og have bekræftet om de leverer det jeg tror og håber

                1 Reply Last reply
                0
                • nohopeN Offline
                  nohopeN Offline
                  nohope
                  wrote on sidst redigeret af
                  #461

                  lyder spændende, tak.

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bassemanden
                    wrote on sidst redigeret af
                    #462

                    meget spændende!

                    1 Reply Last reply
                    0
                    • BudweisB Offline
                      BudweisB Offline
                      Budweis
                      wrote on sidst redigeret af
                      #463

                      Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. http://finance.yahoo.com/news/europe-backs-leukaemia-drugs-j-112026984.html?.tsrc=applewf

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #464

                        Nyt studie ved M.D.Anderson med Ofatumumabhttp://clinicaltrials.gov/ct2/show/NCT02199184?term=ofatumumab&rcv_s=04%2F30%2F2014&rcv_e=07%2F28%2F2014&rank=1

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #465

                          Tak gentogen

                          1 Reply Last reply
                          0
                          • Legolas23L Offline
                            Legolas23L Offline
                            Legolas23
                            wrote on sidst redigeret af
                            #466

                            Godt fundet...

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #467

                              Læs linket....det er ikke sikkert at det ofa studiet kører med !

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #468

                                Det er tilrettelagt med Ofa, men de tager ganske rigtigt et lidt usædvanligt forbehold, idet "Rituximab replaces ofatumumab if insurance does not approve ofatumumab".

                                1 Reply Last reply
                                0
                                • celsiusC Offline
                                  celsiusC Offline
                                  celsius
                                  wrote on sidst redigeret af
                                  #469

                                  hvilken forsikring ????

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #470

                                    Positivt at deres første valg er ofa, men bekymrende hvis de må ty til rtx.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #471

                                      Her lidt fra Morphosys og deres CD38 antistof:

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #472

                                        MOR202 - Combinations with pomalidomide planned

                                        MorphoSys and its collaboration partner Celgene Corporation have decided to expand the clinical development plan of MOR202 in multiple myeloma, introducing pomalidomide as a new combination partner. The MOR202 combination trials are now planned to be initiated earlier than originally anticipated. In addition, cohorts with a weekly dosing schedule, with and without dexamethasone, were added to the ongoing monotherapy trial of MOR202, which continue

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #473

                                          as planned. The expanded design of the trial will be published on www.clinicaltrials.gov. As the now expanded Phase 1/2a trial will not be completed until 2015, the companies do not plan to publish any clinical data this year.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger